nkg2d-based car t-cells
Medulloblastoma
Fudan UniversityCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
42 Active assets in the Medulloblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Pfizer | Phase 2 | BB |
Olaparib Fundación de investigación HM | Phase 2 | BB |
Nivolumab Bristol-Myers Squibb | Phase 2 | B |
Indoximod Theodore S. Johnson | Phase 2 | B |
ETOPOSIDE Theodore S. Johnson | Phase 2 | B |
View all 50 →
Same molecule, other indications
nkg2d-based car t-cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →